Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudsen, Trine Alma, Skov, Vibe, Stevenson, Kristen, Werner, Lillian, Duke, William, Laurore, Charles, Gibson, Christopher J., Nag, Anwesha, Thorner, Aaron R., Wollison, Bruce, Hansen, Dennis Lund, Ellervik, Christina, El Fassi, Daniel, de Stricker, Karin, Ocias, Lukas Frans, Brabrand, Mette, Bjerrum, Ole Weis, Overgaard, Ulrik Malthe, Frederiksen, Mikael, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Thomassen, Mads, Mourits-Andersen, Torben, Severinsen, Marianne Tang, Stentoft, Jesper, Starklint, Joern, Neuberg, Donna S., Kjaer, Lasse, Larsen, Thomas Stauffer, Hasselbalch, Hans Carl, Lindsley, R. Coleman, Mullally, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006286/
https://www.ncbi.nlm.nih.gov/pubmed/34507355
http://dx.doi.org/10.1182/bloodadvances.2021004856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006286/
https://www.ncbi.nlm.nih.gov/pubmed/34507355
http://dx.doi.org/10.1182/bloodadvances.2021004856

Ejemplares similares